Achieve Life Sciences (ACHV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jul, 2026Opening remarks and agenda
The meeting was called to order by the CEO and Chairperson, with the Chief Legal Officer acting as Secretary and the meeting being recorded.
Stockholders were informed about voting procedures and the opportunity to change votes during the meeting.
The agenda included the election of directors, ratification of the auditor, advisory vote on executive compensation, and an amendment to increase authorized shares.
Board and executive committee updates
Director nominees were introduced, including individuals with recent appointments and diverse industry backgrounds.
The board includes executives from various biopharmaceutical and investment firms, with several new directors appointed in 2025 and 2026.
The Inspector of Elections and representatives from the independent auditor and election services were present.
Shareholder proposals
Proposals included electing nine directors, ratifying the independent auditor, approving executive compensation, and amending the certificate of incorporation to increase authorized shares.
Each proposal required a majority or plurality of votes properly cast at the meeting.
Latest events from Achieve Life Sciences
- Net loss of $84.9M, $354M raised, NDA resubmission planned, FDA approval expected H1 2027.ACHV
Q2 2026 - Key votes include board elections, auditor ratification, and doubling authorized common stock.ACHV
Proxy filing - Shareholders will vote on board elections, auditor ratification, executive pay, and a major stock increase.ACHV
Proxy filing - $180M raised for late-stage nicotine dependence drug, with major dilution and market risks.ACHV
Registration filing - $354M raised, U.S. manufacturing advanced, and launch targeted for H1 2027 amid FDA delay.ACHV
Q1 2026 - Cytisinicline targets a vast unmet need with strong efficacy and a 2027 U.S. launch expected.ACHV
Corporate presentation - Cytisinicline NDA accepted; U.S. launch planned for 1H 2027 with supply chain and payer focus.ACHV
Q4 2025 - Cytisinicline offers a novel, effective solution for nicotine dependence with strong market potential.ACHV
Corporate presentation - FDA Breakthrough status, $61.3M cash, and rapid trial progress support NDA plans.ACHV
Q2 2024